Home ›
Entities
› academia
› Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial
Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial
Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial
Summary
Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial is a scholarly article[1].
Key Facts
Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial. Retrieved May 24, 2026, from https://4ort.xyz/entity/temozolomide-with-irinotecan-versus-temozolomide-irinotecan-plus-bevacizumab-for-recurrent-medulloblastoma-of-childhood-
MLA“Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/temozolomide-with-irinotecan-versus-temozolomide-irinotecan-plus-bevacizumab-for-recurrent-medulloblastoma-of-childhood-.
BibTeX@misc{4ortxyz_temozolomide-with-irinotecan-versus-temozolomide-irinotecan-plus-bevacizumab-for-recurrent-medulloblastoma-of-childhood-_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial}}, year = {2026}, url = {https://4ort.xyz/entity/temozolomide-with-irinotecan-versus-temozolomide-irinotecan-plus-bevacizumab-for-recurrent-medulloblastoma-of-childhood-}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial — https://4ort.xyz/entity/temozolomide-with-irinotecan-versus-temozolomide-irinotecan-plus-bevacizumab-for-recurrent-medulloblastoma-of-childhood- (retrieved 2026-05-24)
